
3% sodium
tetradecyl
sulfate; n ¼
292)

Ablation rates at 6 weeks
and 6 months lower
after UGFS; at 5 years,
disease-speciﬁc QoL
was worse after UGFS;
cost-effectiveness
model iteration
favored EVLA

Randomized trial

Gloviczki et al

Journal of Vascular Surgery: Venous and Lymphatic